Renal denervation is a catheter-based minimally invasive procedure. Renal denervation is a novel therapy carried out by radiofrequency or ultrasound ablation for uncontrolled hypertension. The procedure consists of a catheter that emits radiofrequency energy across multiple electrodes. Radiofrequency pulse is applied to the renal artery causing the wall of the artery to ablate, which reduces the nerve activity, thereby reducing blood pressure. The progress of catheter-based interventional therapies yields impressive results in certifying enhanced blood pressure control in patients with complaints of uncontrolled hypertension, vascular, and cardiovascular diseases.
Effective treatment by minimally invasive catheter-based endovascular procedure drives the renal denervation device market
According to the International Journal of Hypertension in 2013, atrial hypertension affects approximately 24.8% of the global population posing morbidity and mortality complications. The rising prevalence of hypertension with inefficient anti-hypertensive medicines, the enduring effect of renal denervation, the fast development of renal denervation devices are the reasons expected to drive the growth of renal denervation devices. The market is expected to grow drastically with the FDA approval of the Symplicity HTN-4 renal denervation device owing to its targeted radiofrequency energy delivery, thereby minimizing the potential threat to surrounding tissues. The market of renal denervation equipment and associated processes is expected to rise owing to the advantages like higher safety, reduced treatment time, permanent effect, and rising incidence of uncontrolled & treatment-resistant hypertension in the urban population due to changing lifestyle habits.
Symplicity system is the largest segment expected to fuel the market owing to the reduction in radiofrequency energy
The global renal denervation devices are segmented on the basis of product type, technology, end-user, and geography.
On the basis of product type, the global renal denervation devices market is segmented into:
- Symplicity Renal Denervation System
- Vessix Renal Denervation System
- Paradise Renal Denervation System
- Iberis Renal Sympathetic Denervation System
On the basis of technology, the global renal denervation devices market is segmented into:
On the basis of end-user, the global renal denervation devices market is segmented into:
- Ambulatory Centers
The rise in research and development for making efficient devices is expected to capture maximum revenue in Europe
On the basis of region, Coherent Market Insights has segmented the global renal denervation devices into North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. The renal denervation devices market in Europe is considered to be the biggest market owing to the increasing drug-resistant hypertension cases and technological advancements in manufacturing efficient devices. According to the American Heart Association, in 2013, around 33% (nearly 70 million people) of the U.S. adult population is suffering from high blood pressure, thus increasing the demand for renal denervation devices in the market. The rising occurrence of uncontrolled hypertension due to rapid urbanization and increasing approvals by FDA is a major factor attributed to the surging market in North America over the forecast period.
Incorporation of the latest innovations in the products is expected to generate higher revenue by the manufacturers
Key players operating the renal denervation devices market include Medtronic plc, St. Jude Medical, ReCor Medical Inc., Boston Scientific Corporation and Cardiosonic Ltd. The leading members are engaged in research and development for introducing innovative and differentiated products in the market. For instance, the launch of HTN-1, Symplicity HTN-2 by Medtronic and EnligHTN TN by St. Jude Medical which have proved efficient and therefore largely adopted by the patients. Other prominent vendors include Ablative Solutions Inc., Mercator MedSystems Inc., Jude Medical Inc., and Terumo Medical Corporation.